CK Life Sciences Int'l. (Holdings) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

CK Life Sciences Int'l. (Holdings) şirketinin toplam hissedar öz sermayesi HK$4.0B ve toplam borcu HK$5.5B olup, bu da borç-öz sermaye oranını 136.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla HK$10.9B ve HK$6.9B dir. CK Life Sciences Int'l. (Holdings) 'in FAVÖK'ü HK$252.4M faiz karşılama oranı 0.7 dur. Şirketin HK$562.1M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

136.3%

Borç/özkaynak oranı

HK$5.47b

Borç

Faiz karşılama oranı	0.7x
Nakit	HK$562.09m
Eşitlik	HK$4.01b
Toplam yükümlülükler	HK$6.87b
Toplam varlıklar	HK$10.89b

Son finansal sağlık güncellemeleri

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

Mar 26

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

Sep 27

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

Sep 16

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

Apr 14

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

Dec 09

Recent updates

CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Oct 04

There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise

May 03

CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Apr 25

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

Mar 26

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

Sep 27

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

Sep 16

Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)

Aug 21

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

Apr 14

CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry

Mar 18

If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns

Feb 01

What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?

Jan 04

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

Dec 09

We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide

Nov 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 775 'nin kısa vadeli varlıkları ( HK$2.8B ) kısa vadeli yükümlülüklerini ( HK$2.9B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 775 'un kısa vadeli varlıkları ( HK$2.8B ) uzun vadeli yükümlülüklerini ( HK$4.0B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 775 'nin net borç/öz sermaye oranı ( 122.3% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 775 şirketinin borç/öz sermaye oranı son 5 yılda 111.2% seviyesinden 136.3% seviyesine yükseldi.

Borç Kapsamı: 775 'nin borcu işletme nakit akışı ( 10.6% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: 775 'in borcuna ilişkin faiz ödemeleri EBIT ( 0.7 x kapsam) tarafından iyi karşılanmıyor.

CK Life Sciences Int'l. (Holdings) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

Recent updates

Now 23% undervalued

VP, CEO & Executive Director recently bought HK$969k worth of stock

Now 21% undervalued

CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

CK Life Sciences Int'l., (Holdings) Inc Announces Director Changes

First half 2024 earnings released: EPS: HK$0 (vs HK$0.004 in 1H 2023)

CK Life Sciences Int'l., (Holdings) Inc. to Report First Half, 2024 Results on Aug 13, 2024

There's No Escaping CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Muted Revenues Despite A 32% Share Price Rise

CK Life Sciences Int'l. (Holdings)'s (HKG:775) Anemic Earnings Might Be Worse Than You Think

Full year 2023 earnings released: EPS: HK$0.002 (vs HK$0.014 in FY 2022)

CK Life Sciences Int'l. (Holdings) (HKG:775) Use Of Debt Could Be Considered Risky

CK Life Sciences Int'l., (Holdings) Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: EPS: HK$0.002 (vs HK$0.014 in FY 2022)

New minor risk - Financial data availability

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

Ck Life Sciences Int'l., (Holdings) Inc. Announces Preclinical Data for Its Investigational Dual-Antigen Cancer Vaccines, Co-Targeting Prame and PD-L1

First half 2023 earnings released: EPS: HK$0.004 (vs HK$0.007 in 1H 2022)

Now 21% undervalued

Full year 2022 earnings released: EPS: HK$0.014 (vs HK$0.017 in FY 2021)

Less than half of directors are independent

Here's Why CK Life Sciences Int'l. (Holdings) (HKG:775) Can Manage Its Debt Responsibly

CK Life Sciences Int'l., (Holdings) Inc. Announces Retirement of Independent Non-Executive Director and Change in Composition of the Remuneration Committee

First half 2022 earnings released

CK Life Sciences Int'l., (Holdings) Inc. to Report First Half, 2022 Results on Aug 02, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.01 per share

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2021 Results on Mar 15, 2022

Now 20% undervalued after recent price drop

Does CK Life Sciences Int'l. (Holdings) (HKG:775) Have A Healthy Balance Sheet?

First half 2021 earnings released: EPS HK$0.01 (vs HK$0.009 in 1H 2020)

Estimating The Intrinsic Value Of CK Life Sciences Int'l., (Holdings) Inc. (HKG:775)

Upcoming dividend of HK$0.01 per share

Full year 2020 earnings released: EPS HK$0.013 (vs HK$0.019 in FY 2019)

These 4 Measures Indicate That CK Life Sciences Int'l. (Holdings) (HKG:775) Is Using Debt Extensively

CK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry

Full year 2020 earnings released: EPS HK$0.013 (vs HK$0.019 in FY 2019)

Ck Life Sciences Int'l., (Holdings) Inc. Recommends Final Dividend for the Year Ended 31 December 2020, Payable on May 31, 2021

CK Life Sciences Int'l., (Holdings) Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

If You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns

What Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?

CK Life Sciences Int'l. (Holdings) (HKG:775) Has A Somewhat Strained Balance Sheet

We Wouldn't Rely On CK Life Sciences Int'l. (Holdings)'s (HKG:775) Statutory Earnings As A Guide

New 90-day low: HK$0.86

CK Life Sciences Int'l., (Holdings) Inc. Announces Directors Changes

New 90-day low: HK$0.89

CK Life Sciences Int'l., (Holdings) Inc. Announces Executive Changes

First half earnings released

CK Life Sciences Int'l., (Holdings) Inc. to Report Q2, 2020 Results on Aug 04, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin